Li Li, Wang Yuanyuan, Wang Shanglong, Zong Jiancheng, Zhang Zengliang, Zou Shengcan, Zhao Zhen, Cao Yu, Liu Zimin
Chenland Nutritionals, Inc., Irvine, CA, USA.
Traditional Chinese Medicine College, Inner Mongolia Medical University, Inner Mongolia, China.
J Integr Complement Med. 2025 Jan;31(1):54-63. doi: 10.1089/jicm.2023.0124. Epub 2024 Oct 14.
Current treatments for osteoarthritis (OA) pain and stiffness have limitations, including adverse effects. Therefore, effective and safe complementary or alternative therapies are needed. Dietary supplement GJ 191, comprising extracts, may address this need. This randomized, double-blind, placebo-controlled study investigated GJ 191 supplementation on knee OA symptoms. Seventy-two adults (40-75 years) with mild to moderate knee OA and mild to moderate knee pain were enrolled. The Knee Injury and Osteoarthritis Outcome Score (KOOS), Pain Visual Analog Scale (VAS), Quality of Life questionnaire, knee joint range of motion, serum C-reactive protein, and rescue medication use were assessed. The Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) pain and stiffness scores were computed using KOOS scores. Decreases in WOMAC pain scores were reported by both GJ 191 and placebo groups after 6 (-1.78 ± 2.71 and -1.34 ± 1.93, respectively; < 0.01) and 12 (-2.31 ± 2.83 and -1.59 ± 2.69, respectively; < 0.01) weeks, with no significant difference between groups. There were decreases in WOMAC stiffness scores for participants supplemented with GJ 191 by 0.53 ± 1.22 and 0.72 ± 1.46 ( ≤0.02) after 6 and 12 weeks, respectively, with respective decreases of 0.81 ± 1.51 and 0.75 ± 1.85 ( ≤0.03) for those on placebo. Significant improvements in current pain, as assessed by the Pain VAS, and bodily pain were reported by the GJ 191 group after 6 and 12 weeks, while the placebo group only reported significant improvements in these measures after 12 weeks. GJ 191 supplementation was safe and well tolerated. There was no significant difference in pain and stiffness scores between GJ 191 and placebo over the 12 weeks. While both groups reported improvements in WOMAC pain from baseline, improvements in current and bodily pain were experienced sooner with GJ 191 than placebo and were sustained over the study period. GJ 191 supplementation was safe and well tolerated. (CTR#: NCT04395547).
骨关节炎(OA)疼痛和僵硬的现有治疗方法存在局限性,包括不良反应。因此,需要有效且安全的补充或替代疗法。包含提取物的膳食补充剂GJ 191可能满足这一需求。这项随机、双盲、安慰剂对照研究调查了补充GJ 191对膝骨关节炎症状的影响。招募了72名年龄在40 - 75岁之间、患有轻至中度膝骨关节炎且伴有轻至中度膝关节疼痛的成年人。评估了膝关节损伤和骨关节炎疗效评分(KOOS)、疼痛视觉模拟量表(VAS)、生活质量问卷、膝关节活动范围、血清C反应蛋白以及急救药物的使用情况。使用KOOS评分计算西安大略和麦克马斯特大学骨关节炎指数(WOMAC)的疼痛和僵硬评分。GJ 191组和安慰剂组在6周(分别为-1.78±2.71和-1.34±1.93;P<0.01)和12周(分别为-2.31±2.83和-1.59±2.69;P<0.01)后WOMAC疼痛评分均有所下降,两组之间无显著差异。补充GJ 191的参与者在6周和12周后WOMAC僵硬评分分别下降了0.53±1.22和0.72±1.46(P≤0.02),安慰剂组分别下降了0.81±1.51和0.75±1.85(P≤0.03)。GJ 191组在6周和12周后,根据疼痛VAS评估的当前疼痛和身体疼痛有显著改善,而安慰剂组仅在12周后这些指标有显著改善。补充GJ 191是安全且耐受性良好的。在12周内,GJ 191组和安慰剂组的疼痛和僵硬评分无显著差异。虽然两组报告的WOMAC疼痛较基线均有改善,但GJ 191组比安慰剂组更早出现当前疼痛和身体疼痛的改善,且在研究期间持续存在。补充GJ 191是安全且耐受性良好的。(临床试验注册号:NCT04395547)